ULTI Stock Overview
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr76.40|
|52 Week High||kr170.20|
|52 Week Low||kr63.20|
|1 Month Change||-9.05%|
|3 Month Change||-17.58%|
|1 Year Change||6.85%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||146.45%|
Recent News & Updates
Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|ULTI||NO Biotechs||NO Market|
Return vs Industry: ULTI exceeded the Norwegian Biotechs industry which returned -50.5% over the past year.
Return vs Market: ULTI underperformed the Norwegian Market which returned 11.9% over the past year.
|ULTI Average Weekly Movement||8.1%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||7.5%|
|10% most volatile stocks in NO Market||12.6%|
|10% least volatile stocks in NO Market||4.3%|
Stable Share Price: ULTI is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ULTI's weekly volatility (8%) has been stable over the past year.
About the Company
|2011||24||Carlos de Sousa||https://ultimovacs.com|
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs Fundamentals Summary
|ULTI fundamental statistics|
Is ULTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ULTI income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 19, 2022
|Earnings per share (EPS)||-4.81|
|Net Profit Margin||0.00%|
How did ULTI perform over the long term?See historical performance and comparison
Is Ultimovacs undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ULTI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ULTI's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ULTI is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ULTI is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ULTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ULTI is overvalued based on its PB Ratio (4.4x) compared to the NO Biotechs industry average (4x).
How is Ultimovacs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ULTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: ULTI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ULTI's is expected to become profitable in the next 3 years.
Revenue vs Market: ULTI is forecast to have no revenue next year.
High Growth Revenue: ULTI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ULTI is forecast to be unprofitable in 3 years.
How has Ultimovacs performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ULTI is currently unprofitable.
Growing Profit Margin: ULTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ULTI is unprofitable, and losses have increased over the past 5 years at a rate of 35.5% per year.
Accelerating Growth: Unable to compare ULTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ULTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: ULTI has a negative Return on Equity (-27.77%), as it is currently unprofitable.
How is Ultimovacs's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ULTI's short term assets (NOK582.3M) exceed its short term liabilities (NOK50.9M).
Long Term Liabilities: ULTI's short term assets (NOK582.3M) exceed its long term liabilities (NOK11.5M).
Debt to Equity History and Analysis
Debt Level: ULTI is debt free.
Reducing Debt: ULTI had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ULTI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ULTI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.7% each year
What is Ultimovacs's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ULTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ULTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ULTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ULTI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ULTI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carlos de Sousa (63 yo)
Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...
CEO Compensation Analysis
Compensation vs Market: Carlos's total compensation ($USD5.44M) is above average for companies of similar size in the Norwegian market ($USD493.99K).
Compensation vs Earnings: Insufficient data to compare Carlos's compensation with company performance.
Experienced Management: ULTI's management team is considered experienced (2.6 years average tenure).
Experienced Board: ULTI's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.
Ultimovacs ASA's employee growth, exchange listings and data sources
- Name: Ultimovacs ASA
- Ticker: ULTI
- Exchange: OB
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr2.615b
- Shares outstanding: 34.22m
- Website: https://ultimovacs.com
Number of Employees
- Ultimovacs ASA
- Ullernchausséen 64
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.